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Functional decline is a strong health determinant in older adults, and chronic diseases play
a major role in this age-related phenomenon. In this study, we explored possible clinical
pathways underlying functional heterogeneity in older adults by quantifying the impact of
cardiovascular (CV) and neuropsychiatric (NP) chronic diseases and their co-occurrence on
trajectories of functional decline.
Methods and findings
We studied 2,385 people60 years (range 60–101 years) participating in the Swedish
National study of Aging and Care in Kungsholmen (SNAC-K). Participants underwent clini-
cal examination at baseline (2001–2004) and every 3 or 6 years for up to 9 years. We
grouped participants on the basis of 7 mutually exclusive clinical patterns of 0, 1, or more
CV and NP diseases and their co-occurrence, from a group without any CV and NP disease
to a group characterised by the presence of CV or NP multimorbidity, accompanied by at
least 1 other CV or NP disorder. The group with no CV and/or NP diseases served as the ref-
erence group. Functional decline was estimated over 9 years of follow-up by measuring
mobility (walking speed, m/s) and independence (ability to carry out six activities of daily liv-
ing [ADL]). Mixed-effect linear regression models were used (1) to explore the individual-
level prognostic predictivity of the different CV and NP clinical patterns at baseline and (2) to
quantify the association between the clinical patterns and functional decline at the group
level by entering the clinical patterns as time-varying measures. During the 9-year follow-up,
participants with multiple CV and NP diseases had the steepest decline in walking speed
(up to 0.7 m/s; p < 0.001) and ADL independence (up to three impairments in ADL, p <
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0.001) (reference group: participants without any CV and NP disease). When the clinical
patterns were analyzed as time varying, isolated CV multimorbidity impacted only walking
speed (β −0.1; p < 0.001). Conversely, all the clinical patterns that included at least 1 NP dis-
ease were significantly associated with decline in both walking speed (β −0.21–−0.08; p <
0.001) and ADL independence (β −0.27–−0.06; p < 0.05). Groups with the most complex
clinical patterns had 5%–20% lower functioning at follow-up than the reference group. Key
limitations of the study include that we did not take into account the specific weight of single
diseases and their severity and that the exclusion of participants with less than 2 assess-
ments may have led to an underestimation of the tested associations.
Conclusions
In older adults, different patterns of CV and NP morbidity lead to different trajectories of
functional decline over time, a finding that explains part of the heterogeneity observed in
older adults’ functionality. NP diseases, alone or in association, are prevalent and major
determinants of functional decline, whereas isolated CV multimorbidity is associated only
with declines in mobility.
Author summary
Why was this study done?
• The accumulation of chronic diseases, a condition called multimorbidity, is common in
older age. Multimorbidity has a negative impact on older people’s health and quality of
life.
• Cardiovascular and neuropsychiatric diseases are common and burdensome in older
people and tend to cluster in the same persons.
• Understanding the associations between cardiovascular and neuropsychiatric multi-
morbidity and functional decline may help to detect groups of older people with poor
prognosis in a timely fashion.
What did the researchers do and find?
• We studied how the increasing number and the combination of cardiovascular and neu-
ropsychiatric diseases are associated with two important measures of physical function
in older people: walking speed and activities of daily living.
• We found that older people with 1 or more neuropsychiatric diseases experience a faster
functional decline than those with cardiovascular diseases. However, when these two
groups of diseases co-occurred, they played a synergistic role in speeding functional
decline.
Multimorbidity and functional decline
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What do these findings mean?
• Neuropsychiatric diseases are major predisposing factors for functional decline in older
people. Both patients and physicians should be aware of that.
• The prompt identification of people with neuropsychiatric multimorbidity, especially in
presence of cardiovascular diseases, may help to buffer the rapid functional decline they
are likely to experience.
Introduction
Aging is accompanied by a number of cellular and molecular dysfunctions that are responsible
for a progressive loss of physical and cognitive resilience [1]. When death does not occur,
physical decline and disability become progressively more frequent and strongly impact peo-
ple’s health [2]. However, even if the direction of this process is certain, its pace varies among
individuals, and both individual and contextual factors play a role in this variation [2]. The co-
occurrence of multiple age-related chronic diseases is one of these factors.
Approximately 55%–98% of people aged60 years have at least two chronic diseases (mul-
timorbidity) [3,4]. Chronic diseases result from the interplay between people’s genetic suscep-
tibility and lifelong environmental exposure [5]. The accumulation of chronic diseases over
time is associated with progressive dysfunction in several systems and organs. Moreover, the
co-occurrence of chronic diseases has negative effects on quality of life, frequency of healthcare
use, dependency, and survival, which are greater than the sum of the effects of the individual
diseases [1,4–6]. A large collaborative study that included 1.2 million participants reported
that co-occurring cardio-metabolic diseases had a multiplicative negative impact on survival
[7]. Indeed, chronic diseases do not appear at random but follow specific patterns due to
shared risk factors and common pathophysiological pathways [4,8]. Previous research has con-
sistently found that clusters of cardiovascular (CV) and neuropsychiatric (NP) disease consti-
tute the major patterns of chronic disease in older adults [8].
CV and NP diseases are among the main contributors to the global burden of disability-
adjusted life years (DALYs) in older adults. CV diseases are responsible for 30% and NP dis-
eases for 7% of the years older people live with disability. Because of the swift growth of the
older population, the overall contribution of these diseases to DALYs is expected to double by
2030 [9–10].
The impact of multimorbidity on functional ability has been investigated in several previous
studies. With few exceptions [11–13], the majority reported that functional disability increased
along with the number of chronic conditions [14–17]. However, few studies have investigated
the relationship between multimorbidity and physical performance, and fewer have attempted
to identify the specific clinical patterns associated with worse prognosis [2,18]. We intend to
help fill this gap by identifying specific health profiles that lead to a major risk of functional
decline.
The current study thus aimed to detect the effect and to quantify the impact of different clini-
cal patterns—characterised by the co-occurrence of chronic CV and NP diseases—on trajecto-
ries of functional decline in older adults. Specifically, we studied the co-occurrence of CV and
NP diseases across three different domains of increasing complexity: (1) pure CV morbidity, (2)
pure NP morbidity, and (3) combined CV/NP multimorbidity. Studying the joint impact and
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prognosis of major chronic diseases will provide valuable information to aid clinicians in their
daily counselling and help healthcare systems better target at-risk populations [8].
Materials and methods
Study design and population
We used data from the 9-year follow-up of the population-based Swedish National study of
Aging and Care in Kungsholmen (SNAC-K) [19]. This study consists of community-dwelling
and institutionalised older adults60 years. A random sample from 11 age cohorts born
between 1892 and 1939 (the youngest and the oldest age cohorts were oversampled) living in
the Kungsholmen district (Stockholm, Sweden) was invited to participate to the study. Those
who accepted were evaluated for the first time between 2001 and 2004 and then followed up
every 6 years (those aged <78 years) or every 3 years (those aged78 years) [19]. At baseline,
3,363 people were examined (participation rate, 73%; S1 Text); 978 participants were excluded
because they had been evaluated fewer than 2 times. Those excluded were older and more
likely to be female, to live in an institution, and to have more chronic diseases than those
included in the study (p< 0.001 for all). Fig 1 depicts the flow of participants through the
study. The study was approved by the Regional Ethics Review Board in Stockholm. Partici-
pants in the study completed a written informed consent form as stipulated in the ethical
approval. For participants with prevalent or incident cognitive impairment, consent was
obtained from the next of kin. [19]. The results of the present study were reported in accor-
dance with the STROBE guidelines (S1 Checklist).
Chronic disease assessment
During baseline and follow-up visits, SNAC-K participants underwent comprehensive clinical
and functional assessments carried out by trained physicians, nurses, and neuropsychologists.
Fig 1. Flowchart of study participation over 9 years. Dropouts are due to either refusal of the participant/relative,
loss of contact with the participant, or moving of the participant from the city where the study took place. FU1, follow-
up 1; FU2, follow-up 2; FU3, follow-up 3; SNAC-K, Swedish National study of Aging and Care in Kungsholmen.
https://doi.org/10.1371/journal.pmed.1002503.g001
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Physicians collected information on diagnoses via physical examination, medical history,
examination of medical charts, self-reported information, and/or proxy interviews [19]. Clini-
cal parameters, lab tests, medications, and inpatient and outpatient care data from the Swedish
National Patient Register were also used to identify specific conditions [20]. All diagnoses
were coded in accordance with the International Classification of Diseases, 10th revision
(ICD-10), and classified in accordance with a clinically driven methodology recently proposed
by our group [20]. After this procedure, we identified 7 CV and 12 NP chronic diseases.
Chronic conditions deemed to be risk factors were excluded (e.g., hypertension and dyslipi-
daemia; see S2 Text for details) [20].
We grouped participants into 7 mutually exclusive clinical patterns based on the presence
of 0, 1, or 2 or more CV or NP diseases (Fig 2): (1) no CV/NP diseases (reference pattern), (2)
1 CV disease, (3) 2 or more CV diseases (CV multimorbidity), (4) 1 NP disease, (5) 2 or more
NP diseases (NP multimorbidity), (6) 1 CV and one NP disease (mixed multimorbidity), (7) 2
or more CV or NP diseases, accompanied by at least 1 other NP or CV disease (complex multi-
morbidity). The reference group may also include participants with 1 or more chronic disor-
ders other than CV and NP diseases (see S1 Table for more details). Our hypothesis is that CV
and NP multimorbidity has a group effect on the outcomes that goes beyond the simple count
of diseases and that exceeds the effect of generic multimorbidity (2 or more diseases, not
including CV and NP diseases). This is the rationale for including participants with multimor-
bidity in the control group. Moreover, studying the impact of mixed and complex multimor-
bidity may also provide information on the effect of the number and type of diseases in
participants who have2 CV and/or NP diseases. For the present study, information on
chronic diseases was available at baseline and at the 3- and 6-year follow-ups.
Functional decline
Mobility was assessed with walking speed and independence as the ability to carry out activi-
ties of daily living (ADL). Changes in mobility and dependence were the outcomes of the
Fig 2. Model showing the grouping of chronic diseases. Participants were grouped by patterns of chronic diseases;
that is, by number of CV and NP diseases. CV, cardiovascular; Mult., multimorbidity; NP, neuropsychiatric; Ref.,
reference group.
https://doi.org/10.1371/journal.pmed.1002503.g002
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present study. To assess walking speed, participants were asked to walk 6 meters at their usual
speed, or alternatively, 2.4 meters. The shorter distance was used when participants reported
that they walked slowly or when the assessment was carried out in restricted spaces, such as in
homes or institutions. Walking speed was reported in meters/second. The ADL score was
obtained by summing the number of intact domains from the following list: bathing, dressing,
toileting, continence, transferring from bed, and eating. Both walking speed and ADL were
assessed at baseline and at each follow-up for up to 9 years.
Covariates
Participants’ demographics (i.e., age, sex, and education) were collected through a ques-
tionnaire administered by the nurse [19]. Educational attainment was categorised as ele-
mentary, high school, and university or higher. Living arrangements (i.e., living in the
community or in an institution) were registered. Body mass index (BMI) was obtained by
dividing the participants’ weight by their squared height (kg/m2). A BMI <18.5 kg/m2 was
considered indicative of malnutrition, in accordance with the recommendations of the
European Society for Clinical Nutrition and Metabolism [21]. The total number of medica-
tions was obtained by counting the number of medications used at the moment of the
assessment, coded in accordance with their Anatomical Therapeutic Chemical (ATC) clas-
sification. In the present study, institutionalization, malnutrition, and number of medica-
tions were used as global measures and proxies of disease severity. Data on BMI, living
arrangements, and medications were available at baseline and at the 3- and 6-year follow-
ups. Vital status and date of death were obtained from the Swedish National Cause of
Death Register and linked to SNAC-K data.
Statistical analyses
In a first analysis, trajectories of walking speed and ADL over 9 years were obtained with
multilevel mixed-effect linear regression models. The clinical patterns at baseline were the
exposures, and the analysis was adjusted for baseline age, sex, education, malnutrition, institu-
tionalization, and number of medications. The reference group consisted of participants free
from CV and NP diseases. Follow-up time was modelled through unrestricted cubic splines
with 3 knots (at 0, 3, and 6 years). This analysis assessed how well the clinical patterns pre-
dicted functional decline at the individual level. In a second analysis, the association between
clinical patterns and functional decline at the group level was estimated through mixed-effect
regression models, in which clinical patterns and covariates that might change with time
(i.e., number of medications, malnutrition, and institutionalization) were all included as time
varying. This analysis assessed the cross-sectional association between clinical patterns and
outcomes, considering the evolution of the exposure over time and taking intra- and interindi-
vidual variability into account. Interactions between clinical patterns and sex and age were
tested, and stratified analyses were carried out. A p-value of<0.05 was considered statistically
significant in all analyses. All analyses were carried out with Stata 14.0 (StataCorp LP) for Mic-
rosoft Windows. Compared with the original protocol (S1 Study Protocol), which included
functional decline and mortality as outcomes, we later decided to focus our analyses on func-
tional decline only, including walking speed (and not only disability) as outcome. Compared
with the original plan, we also decided to model our outcomes through linear-mixed models
instead of Cox regressions, in order to get the most from the repeated measures of both walk-
ing speed and ADL.
Multimorbidity and functional decline
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Sensitivity analyses
First, to investigate the role played by individual diseases in the robustness of our results, we
tested the association between the number of CV and NP diseases and functional decline,
excluding participants affected by the most common diseases, one disease at a time. Second, as
death and dropout during follow-up may not have been at random, we repeated the analyses,
excluding those who died or dropped out during follow-up. Third, incontinence occurs more
frequently in females than in males. To check whether this difference had biased any estima-
tion, we repeated the analyses, excluding incontinence from the ADL count.
Results
The mean age of the 2,385 participants was 73 years, and 65% were females (Table 1). As
shown in Table 2, ischemic heart disease (13%), heart failure (7%), and atrial fibrillation (7%)
were the 3 most frequent CV diseases at baseline. Depression and mood disorders (8%),
dementia (6%), and cerebrovascular diseases (5%) were the 3 most frequent NP diseases.
Chronic disease was more prevalent in participants75 years than in younger participants. In
the reference group (participants without CV and/or NP disease), 6% of participants were not
affected by any disease, 17% had 1 disease, and 77% had 2 or more diseases. Chronic kidney
disease (25%), osteoarthritis (13%), and thyroid diseases (9%) were the most common chronic
diseases (S1 Table).
Fig 3 depicts the trajectories of walking speed and ADL over time. Participants with multi-
ple NP diseases, whether or not they combined with CV diseases, had the steepest decline in
both walking speed and ADL. The rate of decline of participants with CV multimorbidity was
significantly higher than that of the control group (participants free from CV and NP diseases),
but only in walking speed. After 9 years, participants with multiple CV and NP diseases had
the most meaningful deterioration in walking speed (up to 0.7 m/s, p< 0.001) and ADL (up to
3 ADL, p< 0.001), as compared with the reference group.
Table 1. Sample characteristics at baseline by patterns of CV and NP chronic diseases.
No CV/NP diseases 1 CV
disease
CV multim. 1 NP
disease
NP multim. Mixed multim. Complex multim. Total
N = 2,385
DEMOGRAPHICS
Sex (female; N and %) 944 (64.6) 129 (53.8) 70 (57.4) 206 (71.3) 83 (83.0) 47 (66.2) 65 (65.0) 1,544 (64.8)
Age (years; mean ± SD) 70.4 ± 9.5 76.7 ± 9.5 80.3 ± 8.4 73.7 ± 11.1 76.7 ± 10.3 79.2 ± 8.9 81.4 ± 9.3 72.9 ± 10.3
Living in institution (N and %) 2 (0.1) 2 (0.8) 2 (1.6) 14 (4.8) 17 (17.0) 5 (7.0) 14 (14.0) 56 (2.4)
EDUCATION
Elementary (N and %) 171 (11.7) 43 (17.9) 27 (22.0) 52 (18.0) 14 (14.0) 17 (23.9) 20 (20.0) 344 (14.4)
High school (N and %) 700 (47.9) 119 (49.6) 65 (53.3) 135 (49.7) 50 (50.0) 38 (53.5) 57 (57.0) 1,164 (48.8)
University or more (N and %) 591 (40.4) 77 (32.1) 30 (24.6) 98 (33.9) 35 (35.0) 15 (21.0) 21 (21.0) 867 (36.4)
CLINICAL AND
FUNCTIONAL ASSESSMENT
Malnutrition (N and %) 22 (1.5) 4 (1.7) 1 (0.8) 5 (1.7) 1 (1.0) 2 (2.8) 4 (4.0) 39 (1.6)
N diseases ¶ (mean ± SD) 2.8 ± 1.7 4.6 ± 1.8 6.8 ± 2.2 4.1 ± 1.8 5.7 ± 1.9 5.7 ± 2.0 7.9 ± 2.0 3.8 ± 2.3
N medications (mean ± SD) 2.5 ± 2.5 5.2 ± 3.1 6.4 ± 3.7 4.1 ± 2.8 6.4 ± 3.7 5.5 ± 2.7 7.7 ± 3.8 3.7 ± 3.2
9 missing values for education.
Malnutrition defined as BMI < 18.5 kg/m2.
¶Number of diseases out of 60 different conditions, including CV and NP diseases, as grouped by Caldero´n-Larrañaga et al. [20].
Abbreviations: BMI, body mass index; CV, cardiovascular; multim., multimorbidity; N, number; NP, neuropsychiatric; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1002503.t001
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Fig 4 shows the association between the clinical patterns and functional decline at the
group level, considering both the clinical patterns and the covariates as time varying. Having 1
CV disease was negatively associated with walking speed, but the association was of marginal
significance (β = −0.03; 95% confidence interval [CI] −0.07–0.00). All other clinical patterns
were significantly negatively associated with walking speed. The strongest associations were
with NP multimorbidity (β = −0.20; 95% CI −0.24–−0.16) and complex multimorbidity (β =
−0.21; 95% CI −0.25–−0.18). All clinical patterns that included at least 1 NP disease were nega-
tively associated with ADL. Mixed multimorbidity (β = −0.20; 95% CI −0.30–−0.11) and com-
plex multimorbidity (β = −0.27; 95% CI −0.34–−0.19) had the strongest associations. Notably,
1 of 4 participants had at least 1 NP disease. In general, participants with the most complex
clinical patterns had 5%–20% lower functioning than those in the reference group.
The interaction and stratified analyses showed that older age and female sex generally
tended to enhance the negative association between the clinical patterns and the outcomes (S2




N = 1,394 (58%)
75+ years
N = 991 (42%)
N P/100 (95% CI) N P/100 (95% CI) N P/100 (95% CI)
CV Diseases
Ischemic heart disease 312 13.1 (11.8–14.5) 102 7.3 (6.0–8.8) 211 21.2 (18.8–24.0)
Heart failure 176 7.4 (6.4–8.5) 27 1.9 (1.3–2.8) 149 15.0 (12.9–17.4)
Atrial fibrillation 168 7.1 (6.0–8.1) 44 3.1 (2.3–4.2) 124 12.5 (10.6–14.7)
Other CV diseases 55 2.3 (1.8–3.0) 16 1.1 (0.7–1.8) 39 3.9 (2.9–5.3)
Cardiac valve diseases 50 2.1 (1.6–2.8) 16 1.1 (0.7–1.9) 34 3.4 (2.5–4.8)
Bradycardias and conduction disorders 30 1.3 (1.0–1.9) 9 0.6 (0.3–1.2) 21 2.1 (1.4–3.2)
Peripheral artery disease 26 1.1 (1.0–1.6) 11 0.8 (0.4–1.4) 15 1.5 (0.9–2.5)
NP DISEASES
Depression and mood disorders 200 8.4 (7.3–9.6) 109 7.8 (6.5–9.3) 91 9.2 (7.6–11.1)
Cerebrovascular disease 140 5.9 (5.0–6.9) 39 2.8 (2.0–3.8) 101 10.2 (8.5–12.2)
Dementia 108 4.5 (3.8–5.5) 10 0.7 (0.4–1.3) 99 10.1 (2.3–12.0)
Neurotic, stress-related, and somatoform disorders 73 3.1 (2.4–3.8) 37 2.7 (1.9–3.6) 36 3.6 (2.6–5.0)
Migraine and facial pain syndromes 50 2.1 (1.6–2.8) 38 2.7 (2.0–3.7) 12 1.2 (0.7–2.1)
Other neurological disorders 42 1.8 (1.3–2.4) 18 1.3 (0.8–2.0) 24 2.4 (1.6–3.6)
Peripheral neuropathy 36 1.5 (1.1–2.1) 14 1.0 (0.6–1.7) 22 2.2 (1.5–3.4)
Other psychiatric and behavioral disorders 35 1.5 (1.1–2.0) 18 1.3 (0.8–2.0) 17 1.7 (1.1–2.7)
Parkinson and parkinsonism 29 1.2 (1.0–1.7) 9 0.6 (0.3–1.2) 20 2.0 (1.3–3.1)
Epilepsy 14 0.6 (0.0–1.0) 7 0.5 (0.2–1.0) 7 0.7 (0.3–1.5)
Schizophrenia and delusional disorders 10 0.4 (0.0–0.8) 4 0.2 (0.1–0.8) 6 0.6 (0.3–1.3)
Multiple sclerosis 2 0.1 (0.0–0.2) 2 0.1 (0.0–0.6) 0 0 (-)
CLINICAL PATTERNS
No CV/NP diseases 1,462 61.3 (60.3–62.3) 1,023 73.3 (71.0–75.6) 439 44.2 (41.2–47.4)
1 CV disease 240 10.0 (8.9–11.3) 101 7.2 (5.9–8.7) 139 14.0 (12.0–16.3)
CVmultimorbidity 122 5.1 (4.3–6.1) 31 2.2 (1.6–3.0) 91 9.2 (7.5–11.1)
1 NP disease 289 12.1 (10.9–13.5) 156 11.1 (9.6–13.0) 133 13.4 (11.4–15.6)
NP multimorbidity 100 4.2 (3.5–5.1) 43 3.1 (2.3–4.1) 57 5.8 (4.5–7.4)
Mixed multimorbidity 72 3.0 (2.4–3.8) 20 1.4 (0.9–0.2) 52 5.2 (4.0–6.8)
Complex multimorbidity 100 4.2 (3.5–5.1) 20 1.4 (0.9–2.2) 80 8.1 (6.5–9.9)
 Details on the definition of listed chronic diseases are reported in S2 Text.
Abbreviations: CV, cardiovascular; NP, neuropsychiatric; P/100, proportion per 100.
https://doi.org/10.1371/journal.pmed.1002503.t002
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and S3 Tables). In a sensitivity analysis, the exclusion of participants with the most prevalent
CV and NP diseases (S1 Fig) did not change the strength of the association between the num-
ber of CV and NP diseases and functional decline. The results of further sensitivity analyses
were consistent with the results of our main analyses.
Discussion
This study showed that patterns of CV and NP morbidity have different associations with
functional decline in older adults over time. The pattern that included multiple CV and NP
diseases was associated with the worst trajectory. NP diseases, alone or in association, are prev-
alent and major correlates of functional decline. Isolated CV multimorbidity was only associ-
ated with changes in mobility. In general, the combination of multiple CV and NP diseases
(mixed and complex multimorbidity) was associated with 5%–20% reduced functioning than
the reference group (people free from CV and NP diseases but with a high prevalence of
generic multimorbidity).
A number of our results were consistent with those of previous studies. First, both CV and
NP diseases were the most prevalent diseases. They also emerged as independent predictors of
poor function in older adults, and NP diseases were stronger predictors than CV diseases [9].
Second, the coexistence of NP diseases boosted the association of each individual condition
with functional decline, which suggests the existence of a biological interaction among NP
Fig 3. Trajectories of walking speed and ADL impairment over 9 years by clinical patterns. Trajectories derived
from multilevel mixed-effect linear regression models adjusted for baseline age, sex, education, malnutrition,
institutionalization, and number of medications. Reference group: participants free from cardiovascular and/or
neuropsychiatric diseases. ADL, activities of daily living; CV, cardiovascular; Multim., multimorbidity; NP,
neuropsychiatric; Ref., reference group.
https://doi.org/10.1371/journal.pmed.1002503.g003
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diseases [22,23]. Third, when impairments in different systems coexist (as in mixed and com-
plex multimorbidity), the association between the clinical patterns and the outcomes surpasses
the sum of the individual associations with the outcomes and also exceeds the effect of generic
multimorbidity [24,25].
Three studies have investigated the impact of multimorbidity patterns on disability, but
none has looked at the impact on physical performance. Jackson et al. reported that CV and
NP patterns—but not musculoskeletal pattern—were the main determinants of dependence in
personal and instrumental ADL in a sample of 7,270 older women from the Australian Longi-
tudinal Study on Women’s Health [22]. Quiñones et al. showed that a pattern of multimorbid-
ity that included depressive symptoms, arthritis, and hypertension was associated with greater
disability than other patterns in a sample of 8,782 older adults participating in the Health and
Fig 4. Association of chronic disease patterns with walking speed and number of intact ADL based on 6-year
repeated measures of disease patterns, covariates, and outcomes. Multilevel mixed-effect linear regression models
adjusted for age, sex, education, malnutrition, institutionalization, and number of medications. The exposure (the
patterns of chronic diseases), the time-varying covariates (institutionalization, malnutrition, and number of
medications), and the outcomes were introduced in the models as repeated measures. Reference group: participants
free from CV/NP diseases. ADL, activities of daily living; CI, confidence interval; CV, cardiovascular; Multim.,
multimorbidity; NP, neuropsychiatric; Ref., reference group.
https://doi.org/10.1371/journal.pmed.1002503.g004
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Retirement Study [2]. The same group showed that in a sample of 4,017 older Medicare benefi-
ciaries, combinations of somatic and mental diseases, in particular cognitive impairment and
dementia, were associated with greater incident disability than combinations of somatic condi-
tions only [25].
Only indirect comparisons can be made between our study and previous studies. In addi-
tion to differences in the sample selection, follow-up duration, and data collection, a number
of aspects of our study require special attention: (1) unlike in previous studies, in which ad hoc
lists of diseases were used, we relied on a comprehensive, clinically driven list of chronic dis-
eases, for which the proof of concept was recently shown in the SNAC-K population [20]. (2)
Our patterns of CV and NP diseases were not built with a data-driven procedure (e.g., factor
analysis or prevalence), and we included all CV and NP diseases deemed chronic in the older
population by Caldero´n-Larrañaga et al. [20]. (3) As opposed to previous studies, to test the
association between disease patterns and functional status at the group level, we also took the
within-individual, time-varying nature of multimorbidity into consideration and accounted
for time variation in covariates (e.g., medication use and institutionalization). People age at
different rates, and as a consequence, the development of multimorbidity follows different tra-
jectories. Capturing the dynamic nature of multimorbidity in clinical and epidemiological
studies is a scientific priority [6, 20].
Aging is a complex and multifaceted process, and underlying it are a large number of bio-
logical deficits that ultimately affect people’s resilience to external stressors [1,2]. The World
Health Organization has defined healthy aging as the “process of developing and maintaining
the functional ability that enables well-being in older age” [26]. Given the wide heterogeneity
of clinical phenotypes in older people, it is preferable to use global measures of functioning to
capture and assess their health status [27,28]. The National Institute for Health and Care Excel-
lence (NICE) issued the first guidelines for the clinical assessment and management of multi-
morbidity in 2016. According to these guidelines, frailty and functional decline are both a
component of multimorbidity and a condition that should be taken into account and assessed
when managing the health and care of older adults with multimorbidity. [29]. In the present
study, we chose walking speed and ADL as indicators of function in older adults. Slow walking
speed is a strong and independent predictor of disability and a measure of physical frailty [28].
As shown by Santoni et al., slow walking speed and dependency in ADL optimally discrimi-
nate older adults’ health across different ages. Walking speed begins to decrease during the
sixth decade of life, whereas ADL impairment tends to become evident only during the eighth
decade [30]. In the present study, the effect of CV diseases and CV multimorbidity was more
evident on mobility than on independence. Adequate walking speed and ADL both involve
several systems and organs, and the integrity of mental, musculoskeletal, and CV functions are
equally required [28,31]. However, unlike for ADL, walking—especially walking at an ade-
quate speed—requires a certain level of CV fitness. The lack of such fitness due to the presence
of 1 or more CV diseases might explain the selective association between CV diseases and
walking speed [32]. NP conditions, on the other hand, were associated with both measures of
functional decline. In particular, there was a clear dose-response association between walking
speed and the higher number of coexisting NP conditions. Severe NP diseases, such as demen-
tia and cerebrovascular disease (e.g., stroke), have a direct impact on quality of life and inde-
pendence and are extremely burdensome, even in the presence of an intact CV system [9].
This finding has direct clinical implications. First, general practitioners and specialists should
assess mobility in patients with multiple NP diseases more often than in others because of the
steeper functional decline they are expected to experience. Similarly, physicians should consider
the potential negative effect of medications for NP diseases on functional decline. Second,
patients with multiple NP diseases and their caregivers are often told about the memory decline
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or NP symptoms they could develop but not about potential functional decline. Enhancing
their awareness of this eventuality may help empower them to postpone or minimise the detri-
mental effects of diseases. For example, patients could ask for interventions to slow functional
decline in the early stages. All these issues have clear public health implications. Finally, consis-
tent with previous findings, the co-occurrence of diseases involving different systems (i.e., CV
and NP) was associated with slower walking speed and greater ADL dependency. However, the
strength of this association largely overlaps with that of NP multimorbidity.
Some limitations of this study need to be mentioned. First, studying the combined effect of
different diseases belonging to the same body system (i.e., CV and NP) prevented us from
looking at the differential impact of individual conditions. For example, we might expect a dif-
ferent prognosis for dementia and depression. However, in sensitivity analyses, excluding
those with the most prevalent diseases, one disease at a time, did not change the association
between the number of CV and NP diseases and the outcomes. This suggests that our hypothe-
sis that homogenous patterns of multimorbidity convey an overall group-specific effect is plau-
sible. Similar findings have been reported previously [7]. Second, we did not take the severity
of diseases into account. However, we adjusted our analyses for a number of factors (i.e., mal-
nutrition, institutionalization, and number of medications) that can be considered indirect
proxies of disease severity and, at the same time, indicators of other comorbid conditions not
explicitly accounted for. The same approach used to estimate the severity of single diseases
might not work in the presence of multimorbidity. For this reason, using global and multiple
proxies of complexity is warranted [33]. In addition, when we tested the overall association
between disease patterns and functional status, these covariates were analyzed as time varying.
Third, the study of the prognosis of heterogeneous and less prevalent disease patterns (i.e.,
mixed and complex multimorbidity) may have introduced some noise into our analyses. How-
ever, the strength and precision of the associations suggests that our hypothesis regarding the
dose-response effect and interaction between multiple CV and NP diseases is plausible. Fourth,
the SNAC-K sample selection (73% participation rate) might have affected the generalizability
of the present study. In particular, nonparticipants had shorter survival (see S1 Text), which
may mean that both multimorbidity and poor physical function were underestimated in the
analyses, partially blunting the associations we observed between the clinical patterns and
functional decline. Fifth, the exclusion of participants with less than 2 assessments may have
led to an underestimation of the association between clinical patterns and walking speed and
ADL, but only at baseline. However, as we were interested in long-term trajectories of func-
tional decline, we believe that this exclusion criterion was reasonable. Notably, in the analyses
that included all SNAC-K participants, the baseline association between clinical patterns and
the outcomes was stronger than the baseline association in the main analysis, but rates of
decline over the follow-up period were similar. Finally, as shown in previous studies, SNAC-K
participants are relatively fit and wealthy. This might further limit the generalizability of our
results to other groups of older adults.
Conclusion
In conclusion, our findings indicate that CV and NP multimorbidity had different associations
with older adults’ health. NP, mixed, and complex multimorbidity were associated with the
highest burden of functional decline, even with respect to participants with high prevalence of
generic multimorbidity. CV diseases were less strongly associated with functional decline than
were NP diseases; CV diseases were only associated with declines in mobility. Moreover, none
of the diseases drove the association between the group to which it belonged and functional
decline. This finding corroborates the idea that identifying patterns of chronic diseases can
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assist in managing the health and care of people with multimorbidity by providing useful prog-
nostic information, highlighting clinical priorities, steering therapeutic interventions, and
helping physicians counsel patients and their families.
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